Kornimate/medical-research-clean huggingface dataset:
implementation of a teacher classroom program to support preschool children with autism or developmental problems

Conditions: Autism Spectrum Disorder; Teacher Training; Teacher Skills in Addressing Child Mental Health Problem; Developmental Disorders

Summary: the incredible years® "helping preschool children with autism" (iy-hpca) program is designed for teachers of children aged 2 to 5 years who have students with autism in their classrooms. the program provides tools to support children with autism. the primary aim of this pilot study is to examine the feasibility of implementing the iy-hpca intervention among teachers of preschool children (typically aged 2 to 5 years) working in mainstream schools. specifically, we aim to assess teachers' engagement, acceptability, and satisfaction with the program. secondarily, we aim to gather preliminary evidence on the program's effectiveness in improving teachers' use of strategies, teacher self-efficacy, and in reducing burnout. we will conduct an exploratory randomized controlled pilot trial. we aim to recruit approximately 40 teachers, and they will be randomly assigned to either an intervention or control group. the intervention consists of six weekly sessions lasting 3 hours each, delivered by clinical psychologists and child psychiatrists specialized in developmental disorders at hospital sant joan de déu, in barcelona. two intervention face-to-face groups will be conducted at hospital sant joan de déu. feasibility outcomes include program attendance, acceptability, and satisfaction (assessed using the incredible years teacher workshop evaluations and the teacher satisfaction questionnaire), as well as fidelity to the intervention delivery (measured with the leader checklist). after the intervention, individual interviews with teachers and group leaders will qualitatively assess satisfaction and experiences with the program. secondary (effectiveness) outcomes include teachers' use of strategies (teacher strategies questionnaire for children with autism), self-efficacy (teacher sense of efficacy scale), and burnout (maslach burnout inventory-educators survey). this study will provide pioneering insights into the implementation of this program within the public mental health and education systems in spain. this will allow the potential implementation of a wider randomized controlled trial in the future at a larger scale.


Eligibility criteria:
inclusion criteria: * teachers working at mainstream schools near the catchment area of hospital sant joan de déu barcelona. * teachers working at mainstream schools with specific programs for children with special needs. * teachers of pre-school children. * teachers willing to participate in the study and signing the inform consent. exclusion criteria: - teachers working at special education centers instead of mainstream schools.

Keywords: autism teacher training developmental disorders randomized controlled trial early intervention mental health
efficacy and safety of deucravacitinib versus placebo in participants with moderate-to-severe scalp psoriasis

Conditions: Psoriasis

Summary: the purpose of this study is to compare the efficacy and safety of deucravacitinib to placebo in participants with moderate-to-severe scalp psoriasis.


Eligibility criteria:
inclusion criteria: 1. men and women diagnosed with stable plaque psoriasis with scalp involvement for 6 months or more. stable psoriasis is defined as no morphology changes or significant flares of disease activity in the opinion of the investigator 2. deemed by the investigator to be a candidate for phototherapy or systemic therapy 3. moderate-to-severe scalp psoriasis as defined by scalp-specific physician's global assessment (ss-pga) ≥ 3; ≥ 20% scalp surface area (ssa); psoriasis scalp severity index (pssi) ≥ 12 at the screening visit and day 1 4. ≥ 3% of body surface area (bsa) involvement at the screening visit and day 1 5. evidence of plaque psoriasis in a non-scalp area 6. failed to respond to, or intolerant of ≥ 1 topical therapy for scalp psoriasis exclusion criteria: * target disease exceptions: 1. has nonplaque psoriasis (ie, guttate, inverse, pustular, erythrodermic or drug-induced psoriasis) at screening or day 1 other protocol-defined inclusion/exclusion criteria apply

Keywords: scalp psoriasis bms-986165 deucravacitinib psoriasis psoriasis special sites
a single center study for the treatment of moderate to severe allergic conjunctivitis (ebi-005-ac-1)

Conditions: Allergic Conjunctivitis

Summary: this is a phase ii single center, randomized, double-masked, vehicle-controlled, parallel, group study to assess the efficacy of ebi-005 topical ophthalmic solution for the treatment of moderate to severe allergic conjunctivitis using an environmental exposure chamber (eec) model and conjunctival allergen provocation test (capt) model. approximately 150 subjects will be enrolled and randomized in one study center in canada for a duration of 0.33 years.


Eligibility criteria:
inclusion criteria: * provide written informed consent prior to any study-related procedures. * be 18 years of age or older. * have at least a 2 year history of moderate to severe allergic conjunctivitis. * have a positive skin prick test to ragweed within the past 12 months of screening (visit 1a). * have a score of ≥ 2 for staff-assessed ocular redness in at least one region (nasal or temporal) in each eye and ≥ 2 for subject-assessed ocular itching within the 3.5-hour period of allergen exposure in the eec at visit 1b. * have required more than one anti-allergy pharmaceutical treatments in the past 2 years to treat ocular symptoms (including oral, topical, nasal treatments). * be able to self-administer topical ophthalmic drops. * avoid any topical or systemic ocular medications during the entire study period. * are willing and able to follow instructions and can be present for the required study visits for the duration of the study. exclusion criteria: * are female and of childbearing potential and unwilling to remain abstinent through 30 days following the last dose of study drug or not willing to use acceptable birth control methods. * have previously used an il-1 blocker (e.g., anakinra, rilonacept, or ilaris). * have a known contraindication or hypersensitivities to anakinra (kineret®) or any therapeutic agent targeted to il-1 or any component of study drug formulation. * current participation in another clinical study involving an experimental treatment or participation in such a study within 30 days prior to study entry. * require concomitant use of tnf-blocking agents (e.g., etanercept, adalimumab, infliximab). * have a history of glaucoma or intraocular pressure (iop) \> 25 mmhg at the visit 1a (medical screening) or a history of elevated iop within the past year. * have had ocular surgery including laser procedures within the past 12 months of visit 1a (medical screening). * have had contact lens wear within 4 weeks prior to visit 1a (medical screening) or unwilling to discontinue wear during the study period

Keywords: allergic conjunctivitis interleukin 1 receptor inhibitor environmental exposure chamber conjunctival allergen provocation test
clinical signs and symptoms of anemia in patients over 75 years

Conditions: Anemia

Summary: anemia is a common pathology in geriatrics. according to the world health organization it affects 23.9% of subjects over 60 years in the world, and 8% of patients over 60 years in europe. a prevalence that increases with the age and twice in individuals over 85 years.


Eligibility criteria:
inclusion criteria: * adult over 75 years old, male or female exclusion criteria: * transfusion within 3 months, acute anemia / deglobulisation

Keywords: anemia hematologic diseases erythrocytes hemoglobin hemolytic
effectiveness of auricular point acupressure in improving quality of life in patients with pancreatic cancer

Conditions: Pancreatic Cancer

Summary: this study will investigate the effectiveness of auricular point acupressure in improving fatigue,sleep quality,physical activity and quality of life in patients with pancreatic cancer under chemotherapy in taiwan. hypothesis: 1. the fatigue in auricular point acupressure group is significant improving than usual-care group at 1st, 2nd, 3rd and 4th week. 2. the sleep quality in auricular point acupressure group is significant improving than usual-care group at 1st, 2nd, 3rd and 4th week. 3. the physical activity in auricular point acupressure group is significant improving than usual-care group at 1st, 2nd, 3rd and 4th week. 4. the quality of life in auricular point acupressure group is significant improving than usual-care group at 1st, 2nd, 3rd and 4th week.

this study will investigate the effectiveness of auricular point acupressure in improving fatigue,sleep quality,physical activity and quality of life in patients with pancreatic cancer under chemotherapy in taiwan.

Eligibility criteria:
inclusion criteria: 1. paitent who aged over 20, with clear consciousness, is capable of communicating with chinese, and is able to perform ear acupoints by himself/herself. 2. pancreatic cancer patients who received chemotherapy in inpatient and outpatient department. 3. the subject who agrees and is willing to participate in the research after explaining the purpose of the research. exclusion criteria: 1. patient who is younger than 20 years old, illiterate, or is unable to cooperate with intervention measures. 2. patient who is not suitable for ear acupoint pressing after evaluated by the attending physician.

Keywords: chemotherapy fatigue sleep quality physical activity quality of life
evaluation of topical b12 for the treatment of childhood atopic dermatitis

Conditions: Eczema

Summary: this study is being done to see in b12 applied to the skin will improve the symptoms of eczema in children compared to a placebo creme

introduction: atopic dermatitis is a prevalent disease process in children, affecting up to 20% of children in the united states. various treatment options are available to treat atopic dermatitis to include topical emollients, topical steroids, and topical calcineurin inhibitors. each treatment option has benefits and potential risks. this study was done to determine if topical b12 could be a tolerable and efficacious alternative treatment option in this population. methods: the study was conducted as a placebo-controlled, double-blind, prospective, randomized clinical trial with intraindividual left ⁄ right comparison. parents were given 2 containers of creams and instructed to apply the vitamin b12 cream to one side of the body and the placebo cream to the contralateral side according to the randomization scheme.

Eligibility criteria:
inclusion criteria: * children presenting to the center for family medicine or regional pediatrics between the ages of 6 months and 18 years old with atopic dermatitis exclusion criteria: * unwillingness of parent to consent to study protocol, pregnancy or lactation, eczema with superinfection present, known history of allergy to vitamin b12 or components of the base cream, topical treatment with corticosteroids in the 4 weeks prior to enrollment

Keywords: eczema pediatric vitamin b12
an observational study of rituximab in combination with methotrexate in participants with active rheumatoid arthritis

Conditions: Rheumatoid Arthritis

Summary: this observational study will assess the efficacy and safety of combination of rituximab (mabthera) and methotrexate in participants with active refractory rheumatoid arthritis (ra) who have failed to respond to a single course of anti-tumor necrosis factor (tnf) therapy in routine clinical practice. data will be collected from participants for 12 months after the first dose of rituximab or a minimum of 6 months following a rituximab re-treatment course.


Eligibility criteria:
inclusion criteria: * active rheumatoid arthritis * inadequate response to a single tnf inhibitor * participants receiving rituximab therapy in accordance with the prescribing information * signed data release form within 6 weeks (42 days) of initiating rituximab therapy * women of childbearing potential must use effective form of contraception exclusion criteria: * contra-indication to receive rituximab according to the local labelling * previous treatment with rituximab * treatment with any investigational drug within 30 days prior to enrolment
chatgpt-4 for surgical site infection detection from electronic health records after colorectal surgery.

Conditions: Surgical Site Infection

Summary: epidemiological surveillance is one of the eight core components of the world health organization infection prevention and control programmes. these include surveillance programmes for surgical site infection (ssi). at present, for ssi surveillance, infection control teams perform a manual time-consuming work, which could make a transition to automated surveillance leveraging the new information technology. this study aimed to evaluate the ability of chatgpt-4o to detect surgical site infection at the three anatomical levels.

healthcare-associated infections (hais) have a negative impact on patient health, represent a significant healthcare and economic burden on healthcare systems and are considered the most preventable cause of serious adverse events in hospitalised patients. epidemiological surveillance is one of the eight core components of the world health organization (who) infection prevention and control programmes. these include surveillance programmes for surgical site infection (ssi), which have proven to be effective in all types of surgery and in a variety of settings. for a programme to be effective, surveillance for hcais must be active, prospective and continuous, comprising a surveillance period up to 30-90 days post-intervention, to cover the high rate of ssis detected after discharge. at present, infection control teams perform a manual, prospective, time-consuming and almost artisanal work, which should make a transition to automated or semi-automated surveillance that leverages the possibilities offered by today\&#39;s information technology. the evolution of surveillance systems should benefit from this new possibilities offered by artificial intelligence, allowing automated detection of suspected ssi adverse events from clinical course text, microbiology reports or coding of diagnoses, procedures, complications and readmissions. this study aims to evaluate the ability of chatgpt to detect surgical site infections (ssi) at the three anatomical levels described by the cdc. the study will retrospectively compare the results of the ai chatbot in diagnosing ssi, trained using the us cdc definition criteria, with a large cohort of elective colorectal surgery patients already evaluated through a nationwide nosocomial infection surveillance system, which will be the comparative gold standard.

Eligibility criteria:
inclusion criteria: * elective colorectal resection exclusion criteria: * emergency surgery * infection present at operation * previous intestinal stoma

Keywords: surgical site infection surveillance chatgpt natural language processing artificial inteligence
scapular movement training versus general exercises for individuals with shoulder pain

Conditions: Shoulder Pain; Musculoskeletal Disease; Joint Disease; Shoulder Injury

Summary: interventions focused on the scapula have been frequently used to treat shoulder pain. however, most studies do not assess the contribution of scapular movement alteration for the symptoms. objectives: to compare the effects of two interventions for shoulder pain: scapular movement training and general exercises.

this is a double-blinded randomized controlled trial. sixty-four subjects with shoulder pain, scapular dyskinesis, and positive scapular assistance test will be randomized in two groups: 1) scapular movement training, and 2) general exercises. the scapular movement training group will receive the orientation about proper scapular position and movement, and will be trained to modify the scapular movement pattern. the general exercises group will perform scapulothoracic stretching and strengthening exercises. both groups will be treated twice a week for eight weeks. the following outcomes will be collected at baseline and follow-up: scapular kinematics, electromyographic muscle activity of the upper, middle and lower trapezius, and serratus anterior, as well as pain intensity, function, and fear avoidance beliefs. also, pain intensity, function, and fear-avoidance beliefs will be assessed at the fourth week of follow-up after the end of treatment's period.

Eligibility criteria:
inclusion criteria: * shoulder pain intensity ≥ 3 points on numerical rating scale; * shoulder pain lasting ≥ 3 months; * scapular dyskinesis; * positive scapular assistance test; * arm elevation ≥ 150°; exclusion criteria: * body mass index \> 28kg/m * history of humerus, clavicle and scapula fracture and/or surgery; * history of rotator cuff surgery or tears, shoulder dislocation, and instability; * frozen shoulder; * neurological or systemic disease which may alter the muscle strength and sensibility; * positive upper limb tension test and/or spurling's test * pregnancy; * physical therapy within 6 months; * corticosteroid injection within 3 months * transpore tape allergy;

Keywords: scapula physical therapy movement rehabilitation
optimal initiation of helicobacter pylori eradication after endoscopic resection for gastric neoplasm

Conditions: H.Pylori Eradication Rate

Summary: after endoscopic resection (er) of gastric tumors, eradication of helicobacter pylori (h. pylori) infection is advised to reduce metachronous recurrence. however, few studies have addressed factors influencing h. pylori eradication rates in the aftermath of er, and none have focused on the optimal timing of therapy to eradicate h. pylori post-er.therefore, the investigators will conduct to evaluate whether differences in timing of eradication therapy after er of gastric tumors.

uur previous retrospective study unveiled that administering eradication treatment within 2 weeks post-esd during the active reparative phase of esd-induced ulcers yielded a markedly higher success rate compared to treatment post-8 weeks during the scarring phase of esd-induced ulcers.therefore, we conducted a multicenter, randomized, prospective study to ascertain whether the optimal timing of eradication post-esd could influence the eradication success rate.

Eligibility criteria:
inclusion criteria: 1. patients underwent endoscopic resection of gastric neoplasm 2. patients who diagnosed as h. pylori infection by rapid urease test exclusion criteria: 1. histories of gastric surgery 2. histories of prior h. pylori eradication therapy 3. use of drugs affecting h. pylori positivity (proton pump inhibitor, histamine-2 receptor blocker, or antibiotics) within the preceding 2 weeks
moxonidine for prevention of post-ablation afib recurrences

Conditions: Atrial Fibrillation

Summary: hypothesis: modulation of central nervous sympathetic activation by administration of moxonidine, a centrally acting medication which decreases the sympathetic nervous system activity, can lead to a decrease in atrial fibrillation recurrence after ablation treatment with pulmonary vein isolation.


Eligibility criteria:
inclusion criteria: * hypertensive patients with paroxysmal atrial fibrillation. * at least two documented episodes within the last 12 months (either self-terminating within 7 days or cardioverted, medically or electrically, in less than 48 hours). * at least one episode should have been documented under treatment with a class ic or iii antiarrhythmic drug. exclusion criteria: 1. age \ 80 years 2. presence of atrial thrombus 3. left atrial volume index \>55 ml/m2 4. hypersensitivity to moxonidine 5. sick sinus syndrome or sino-atrial block 6. 2nd or 3rd degree atrioventricular block 7. bradycardia (below 50 beats/minute at rest) 8. estimated glomerular filtration rate \<40 ml/min/1.73 m2 9. history of angioneurotic oedema 10. heart failure symptoms or impaired left ventricular function (ef \<40%), even if asymptomatic 11. stable or unstable angina pectoris 12. intermittent claudication or known peripheral artery disease 13. parkinson's disease 14. epileptic disorders 15. glaucoma 16. history of depression 17. pregnancy or lactation 18. inability or unwillingness to adhere to standard treatment or to provide consent.

Keywords: atrial fibrillation paroxysmal persistent ablation pulmonary vein isolation recurrence
cv events in emetogenic chemotherapy

Conditions: Vomiting; Cardiovascular Event; Arterial Thromboembolic Event

Summary: describe cardiovascular events in a cancer population receiving highly emetogenic chemotherapy (hec) or moderately emetogenic chemotherapy (mec).

patients were not recruited for nor enrolled in this study. this study is a retrospective observational study. data from medical records or insurance claims databases are anonymised and used to develop a patient cohort. all diagnoses and treatment are recorded in the course of routine medical practice.

Eligibility criteria:
inclusion criteria: * enrollment in ihcis in 2006 * at least one hec or mec claim in 2006 exclusion criteria: * hec or mec claim three months before first hec/mec claim - "wash-in" period (i.e. must be enrolled for three months prior to first hec/mec claim. for patients whose first hec/mec event is between january 1,2006 and march 31, 2006, enrollment criteria for inclusion in the study may extend as far back as october 1, 2005) * hec or mec claims prior to 45 days after last hec or mec claim - "wash-out" period. (for patients whose last claim in 2006 was seen after december 1, 2006 enrollment into 2007 to look for further treatment and the 45 day "wash-out" period will be required.)

Keywords: highly emetogenic chemotherapy hec moderately emetogenic chemotherapy mec
interscalene block versus combined supraprascapular: axillary nerve blocks

Conditions: Analgesia; Diaphragm

Summary: the interscalene block provides effective analgesia after shoulder surgery. it consists of injecting local anaesthetic within the brachial plexus, in the interscalene groove, between the anterior and middle scalene muscles. unfortunately, this technique is associated with respiratory complications such as hemidiaphragmatic paresis due to the spread of the local anaesthetic towards the phrenic nerve that lies close to the brachial plexus, with an incidence up to 100%. the diaphragmatic paresis may be a serious side-effect, especially in patients suffering from a reduced respiratory function such as chronic obstructive pulmonary disease; this entity may even represent a contraindication to the performance of the block. the shoulder is mainly innervated by the suprascapular and axillary nerves, both of them coming from c5 and c6 branches of the brachial plexus block. recently, several authors have successfully identified and block these two nerves under ultrasound guidance. only one randomised controlled trial compared interscalene block with a combination of suprascapular and axillary nerve blocks, and showed inconclusive results probably due to the absence of ultrasound guidance; indeed, analgesia was equivalent at the sixth postoperative hour, while patients with an interscalene block had reduced pain scores in the recovery room. besides, the authors did not investigate the impact on the respiratory function. in that randomised controlled trial, the investigators would like to compare the analgesic efficacy and the respiratory outcomes between the interscalene block and the combined suprascapular-axillary nerve blocks.


Eligibility criteria:
inclusion criteria: * asa physical status i-iii; * 18-85 years of age, inclusive; * surgery less than 3 hours. exclusion criteria: * indication for catheter insertion; * contraindications to brachial plexus block (e.g., allergy to local anaesthetics, malignancy or infection in the area); * existing neurological deficit in the area to be blocked; * pregnancy; * history of neck surgery or radiotherapy; * severe respiratory disease; * chest deformity; * inability to understand the informed consent and demands of the study; * patient refusal.